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ABSTRACT
Introduction: Many patients need more than
one antihypertensive agent for effective blood
pressure (BP) control. Prescription of a
fixed-dose combination (FDC) of bisoprolol
and amlodipine in one tablet has been shown
to significantly improve patient adherence. This
non-interventional study investigated the
effects on adherence and BP control of
switching from a free-dose combination of the
two antihypertensive substances to a FDC in a
larger patient population.
Methods: Patients aged C18 years with
essential hypertension were switched at least
4 weeks prior to study initiation from a
free-dose combination of bisoprolol and
amlodipine to the FDC. Dosage adjustment
was implemented only if medically indicated.
Adherence was assessed on the basis of the ratio
of pills used to pills dispensed (%) at each visit
(pill count). BP and key laboratory values were
determined at baseline, 3 and 6 months.
Results: 10,532 patients (average age 59 years;
48% female) were recruited between 2013 and
2014; 22% of patients had type 2 diabetes and
38% had cardiovascular disease. The mean
doses of the freely combined drugs prior to
switching were 5.5 mg bisoprolol and 6.1 mg
amlodipine once daily. The mean daily doses
prescribed in the FDC were 5.8 and 6.4 mg,
respectively. Pill counts at 6 months revealed a
good to excellent adherence in [95% of the
patients. Comparison of BP at baseline and at
6 months showed substantial changes (mean
systolic BP: 147.3 vs. 130.9 mmHg; mean
diastolic BP: 87.9 vs. 79.1 mmHg). Clinically
relevant improvement in systolic BP was
established for 82% of patients. In patients
with comorbidities, switching to FDC
produced a substantial improvement in BP. A
total of 89 (0.7%) adverse events (AEs) were
reported, including edema, headache, dizziness,
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bradycardia, nausea, and skin reactions. Only
three AEs were classified as serious.
Conclusion: These data from a
non-interventional study in a large patient
population demonstrate the benefits of
prescribing a FDC of bisoprolol–amlodipine in
terms of an excellent adherence and an
associated improvement in control of
previously elevated BP, which may be relevant
in real-life practice.
Funding: Merck KGaA.
Keywords: Adherence; Amlodipine; Bisoprolol;
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INTRODUCTION
For a number of medical research questions, the
results produced by the ‘‘gold standard’’ of
clinical research—randomized, double-blind,
controlled trials (RCTs) of drugs or medical
applications—are limited in the evidence they
provide regarding potential applications and
effects, risks, and patient adherence in a routine
medical setting [1, 2]. Without diminishing the
importance and necessity of RCTs in
documenting the efficacy and safety of
medicinal products, there is a consensus that
additional data are required from studies in
patients whose diagnosis, treatment, and
monitoring exclusively follow normal medical
practice [3], while the patients involved benefit
from the increased therapeutic freedom versus
participation in a RCT.
Carefully planned, conducted, and evaluated
non-interventional studies may be particularly
useful in drawing conclusions regarding the
effects, safety, and—in some cases—acceptance
of therapeutic procedures, medicinal products,
or medical devices, based on immediate
observation of a wide range of individual
circumstances and not on findings in a specific
selection of clinical trial patients chosen to
meet strictly defined criteria. In a
non-interventional study, the medical
procedures carried out have the sole purpose
of providing the best possible care for the
individual patient. Non-interventional studies
include a varied range of patients with and
without comorbidities and do not dictate
additional interventions or instructions
beyond the treatment concept based on the
needs of the patients concerned. Regulatory
authorities in many countries now require
non-interventional studies—in most cases
following the approval of a new drug—and
study design guidelines are now available [4].
Systematic analysis of data from RCTs versus
non-interventional studies has shown virtually
no evidence of superiority of RCTs in terms of
assessing the effects of medicinal products [5].
This conclusion applies regardless of the specific
design, study population criteria, and data
acquisition periods.
Non-interventional studies are conducted in
various designs. One such format is a cohort
study, in which participants undergo specific
medical care and their outcome is monitored
and evaluated at certain times [1, 6, 7]. A
prerequisite is that the expected effects in
real-life conditions are largely similar to those
investigated in RCTs and that the investigating
sites are qualified to use the investigational
material. This helps to minimize the dropout
rate. Non-interventional studies of this kind
generally involve large sample sizes and may
therefore help to identify rare adverse events
(AEs).
Event rates in non-interventional studies
may also indicate effects and/or risks
attributable to certain factors that do not
feature in RCTs because of the strict exclusion
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criteria. Non-interventional studies, for
instance, enable adherence to a new
medication or formulation to be analyzed in
real life and correlated with treatment response
or other parameters. These data may be
important if the success of a prescribed
long-term therapy very much depends on
adherence with the regimen, e.g., in the
treatment of patients with hypertension.
Hypertension is one of the most common
conditions seen in primary care. Untreated, it
is associated with a high risk of myocardial
infarction, stroke, renal failure, and premature
death [8, 9]. There is an abundance of evidence
showing that blood pressure (BP) should be
below 150/90 mmHg in patients aged
C60 years. The corresponding level for
younger patients and people with diabetes or
renal failure is 140/90 mmHg [10].
Clinical trial results show that a very large
proportion of patients receiving
antihypertensive treatment from primary care
physicians do not achieve these recommended
BP levels [11, 12]. Many patients require more
than one antihypertensive drug for successful
BP control [13, 14] in a regimen encompassing
different pharmacologic mechanisms of action.
A combination of a beta-blocker such as
bisoprolol with a calcium channel blocker
such as amlodipine is an established option for
successful drug treatment of patients with high
BP [15]. It is also cited repeatedly in
international guidelines [10]. However,
prescribing this free-drug treatment regimen
presents an adherence challenge for patients,
which may considerably jeopardize the desired
treatment response [16]. Hence, it seemed
justified to develop and investigate a
fixed-dose combination (FDC) of the two
active substances in all potentially
administered dosage regimens (bisoprolol plus
amlodipine: 5 ? 5 mg, 10 ? 5 mg, 5 ? 10 mg,
10 ? 10 mg). These FDCs were tested in
various clinical trials [17–19] and produced a
significant reduction in previously elevated BP
at the respective dose levels employed. The
FDCs also achieved better results than regimens
based on a free-dose combination of the two
agents.
To produce additional evidence for these
FDCs, an extensive non-interventional study
was conducted involving two chronologically
separate periods. The first part of the study was
evaluated after 4288 patients had been enrolled
and treated for 6 months [20]. Monitoring of
the percentage of tablets taken at 6 months
revealed a very high rate of good to excellent
adherence ([95%). At the same time, a
clinically relevant decline in previously
elevated BP was noted (systolic 15%, diastolic
11%), although most patients had been
receiving the same doses of bisoprolol and
amlodipine in a free combination.
To further verify the accuracy of these
results, the study was continued at the same
sites, and a number of new sites were added to
include results for around 10,000 patients. This
enabled data from the first study period to be
checked against the data for the whole of this
non-interventional study.
METHODS
The plan for this non-interventional study
proposed individualized antihypertensive
treatment in terms of procedures, dosages,
follow-up, and final assessment with four
different regimens of the active substances
bisoprolol and amlodipine in a FDC: 5 mg
bisoprolol plus 5 mg amlodipine, 5 mg
bisoprolol plus 10 mg amlodipine, 10 mg
bisoprolol plus 5 mg amlodipine, and 10 mg
bisoprolol plus 10 mg amlodipine. No
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additional measures departing from routine
care in this patient population were proposed.
Investigating sites were at liberty to choose any
necessary medical interventions or additional
drugs as they saw fit.
Patients aged C18 years with essential
hypertension were recruited if they had
already been switched from a free combination
of bisoprolol 5–10 mg/day and amlodipine
5–10 mg/day to the FDC at least 4 weeks prior
to recruitment. Reliable contraception was
mandatory in women of childbearing age.
Exclusion criteria included pregnancy,
lactation, any contraindication to the FDC
according to the local label, and any other
antihypertensive medication.
The primary endpoint was patient adherence
under the FDC measured by tablet count
(tablets taken/tablets prescribed 9 100) and
defined as follows: excellent [90%, good
76–90%, moderate 51–75%, and bad B50%. BP
was measured in a supine position after at least
5 min rest. All other patient data, clinical
findings, and laboratory values were recorded
upon availability at study start, after 3 months
(voluntary), and after 6 months into case record
forms (CRFs). Upon completion of the study, all
the entries from the CRFs were transferred to an
assessment table (BIAS: Biometric Analysis of
Samples, Hanns Ackermann, Frankfurt,
Germany).
Access to patient data was restricted
exclusively to the investigators. All patients
were assigned an ID number before the study
to enable anonymous documentation for
evaluation purposes. Patients were informed
about these data protection measures at the
start of the study and asked to sign a consent
form to participate in accordance with the
conditions described. All procedures followed
were in accordance with the ethical standards of
the responsible committee on human
experimentation (institutional and national)
and with the Helsinki Declaration of 1964, as
revised in 2013. Informed consent was obtained
from all patients for being included in the
study.
For data analysis, calculation of means with
standard deviations, medians with quartiles and
Spearman’s correlation analyses,
Mantel–Haenszel test for contingency tables,
and Cohen’s D for effect size were used.
RESULTS
This multicenter non-interventional study
included 10,532 patients who were treated in
68 Polish centers. The demographic data of the
patients are summarized in Table 1. The mean
age was 59 years, with a broad range from 19 to
99 years. There was almost no correlation
between BP values and patient age. As shown
by the median body mass index (BMI), most of
the patients were overweight. Dependence of BP
values on BMI could not be determined. A large
proportion of patients had concomitant
cardiovascular diseases (N = 4011, 38.1%) or
type 2 diabetes (N = 2313, 22%). Angina
pectoris (12.3%) and arrhythmia (11.1%) were
the most frequent concomitant cardiovascular
diseases.
Prior to the switch to the FDC, all patients
had been pretreated with a free combination of
bisoprolol (mean 5.5 mg once daily) and
amlodipine (mean 6.1 mg once daily). The
lowest possible dose (5 mg bisoprolol and 5 mg
amlodipine once daily) was prescribed for the
majority of patients (75%); data in Table 1 show
that most patients did not reach the target value
for systolic BP below 140 mmHg. The average
dose in the FDC after switching from the free
dose was 5.8 ± 2 mg bisoprolol and 6.4 ± 3 mg
amlodipine once daily. In this respect, the
switch to the FDC was only associated with
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Table 1 Demographic data
Parameter N (%)
Participants 10,532
Female 5050 (47.9)
Male 5435 (52.1)
Diabetes type 2 2313 (22)
Cardiovascular comorbidities 4011 (38.1)
Liver disease 157 (1.5)
Kidney damage 347 (3.3)
Smoking status
Non-smoker 4962 (47.1)
Smoker 2.690 (25.5)
Ex-smoker 2799 (26.6)
No data 81 (0.8)
Alcohol consumption
None 3779 (35.9)
Not regularly (0–19 weekly) 5374 (51.1)
Regularly (2–79 weekly) 1295 (12.2)
No data 84 (0.8)
Parameter Mean (–SD) Median Q1–Q3
Age (years) 59 (11) 59 52–67
Height (cm) 170.1 (17) 170 164–177
Weight (kg) 81.3 (15) 80 72–90
BMI (kg/m2) 28.1 (4) 28 25.5–30
Systolic BP (mmHg) 147.3 (15) 148 139–160
Diastolic BP (mmHg) 88.6 (10) 90 80–95
Pulse (beats/minute) 76 (10) 76 68–82
Fasting glucose (mg/dL) (N = 2429) 99.1 (21) 96 88–105
Duration of hypertension (years 9.2 (5) 7 2.5–12
Duration of free combination treatment prior to switch (months) 19.5 (22) 14 7–24
Dosages (free combination) (mg/day)
Bisoprolol 5.5 (2) 5 5–5
Amlodipine 6.1 (2) 5 5–5
BMI body mass index, BP blood pressure, SD standard deviation
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minimal dose modification. Thus, when
switching from the free to the FDC, no
changes in bisoprolol or amlodipine doses
were performed in 84% of patients. A
correlation between the amount of the
respective doses of bisoprolol and amlodipine
on BP values before study entry could not be
detected.
At the end of the study (Visit 3 after
6 months), data on patient adherence were
available for 8830 (82.2%) patients (Table 2).
Overall, 3710 patients attended Visit 2 after
3 months, as well as Visit 3 after 6 months.
Adherence was stable between the second and
the third visits; 80.3% of patients showed an
equal share of tablet consumption in both
controls. A comparison of the adherence
ratings did not show any difference between
male and female patients.
The analysis of data for BP control showed a
clinically relevant regression of systolic and
diastolic values, although no considerable dose
changes were made during the study period
(Table 3). BP was measured in a supine position
after at least 5 min of rest. Figure 1 shows the
proportion of patients with systolic BP changes
after 6 months of FDC treatment. It is
noteworthy that BP reductions were confirmed
for all drug doses tested (Table 4).
Accordingly, remarkable differences can be
registered regarding the proportions of patients
per quartile between the values at study start
and after 6 month if the subdivision of quartiles
at study start is maintained (Fig. 2). The
reductions in diastolic BP were very similar to
the reductions in systolic BP shown in Fig. 2.
There was a noticeable correlation between BP
values prior to the study and the extent of their
decline (r 0.8).
The importance of adherence for good BP
control becomes particularly evident when
comparing BP values as a function of patient’s
behavior. Although only 2% of patients showed
moderate or poor adherence, their BP
measurements were remarkably higher than
those of patients with good to excellent
adherence (Table 5). The benefits of adherence
on BP control are confirmed by the
improvement in pulse pressure by an average
of 58.7 mmHG ± 13 (median 60) at study start
versus 51.7 mmHg ± 11 (median 50) after
6 months of treatment. All patients were asked
whether they would choose the free
combination or the FDC; approximately 97%
of patients preferred the FDC.
Although all patients had been treated with a
free-dose combination of bisoprolol and
amlodipine and switched to the FDC at least
Table 2 Patient adherence at Visit 3 (after 6 months)
Adherence (% of prescribed tablets taken) N (%)
Excellent ([90%) 7562 (85.6)
Good (76–90%) 1098 (12.4)
Good to excellent (C76%) 8660 (98.1)
Moderate (51–75%) 145 (1.7)
Bad (\50%) 25 (0.3)
Total 8830 (100.0)
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4 weeks before starting the study, BP
measurement at study start showed differences
in systolic readings, which were attributable to
the respective comorbidities (Table 6). In
contrast, patients who reported none of the
listed comorbidities had a lower systolic BP
(average 145 ± 10 mmHg).
After 6 months of treatment with the FDC of
bisoprolol and amlodipine with no major dose
changes, differences in systolic BP in relation to
comorbidities were no longer evident (with
diabetes 130.5 ± 10 mmHg, without diabetes
131.9 ± 10 mmHg; with cardiovascular diseases
130.4 ± 10 mmHg, without cardiovascular
diseases 131.5 ± 10 mmHg; with renal diseases
130.9 ± 10 mmHg, without renal diseases
131.2 ± 11 mmHg).
Another improvement observed during the
study was a considerable reduction in heart rate
from an average of 75 ± 10 to 68.6 ± 10 bpm,
which can also help to reduce the health risk for
these patients.
Safety Evaluation
In total, 89 AEs were reported in 70 patients
(0.7%). The majority of these were edema (41,
46.1%), headache (7, 7.8%), dizziness (6, 6.7%),
and bradycardia, nausea, and skin burning/
redness (4, 4.5% each). Only three AEs (3.4%)
were considered serious, one case of atrial
fibrillation (not related), one case of chronic
heart failure worsening, and one head injury
leading to death (not related). Just nine patients
(0.09%) discontinued the study due to AEs,
including lower limb or ankle swelling or other
edema, nausea/malaise, skin burning/redness/
Table 3 BP at study start and after 6 months
Systolic BP (mmHg)
N5 9435
Diastolic BP (mmHg)
N5 9585
Mean (–SD) Mean (–SD)
Visit 1 (Study start) 147.3 (15) 87.9 (10)
Visit 3 (after 6 months) 130.9 (10) 79.1 (7)
Difference before–after 16.6 (16) 9.5 (11)
Systolic BP (mmHg)
N5 9435
Diastolic BP (mmHg)
N5 9585
N (%) N (%)
Improvement 7754 (82.2) 7010 (73.2)
No change 884 (9.4) 1478 (15.4)
Worsening 797 (8.4) 1097 (11.4)
BP blood pressure, SD standard deviation
Fig. 1 Changes in systolic blood pressure as 6 months
ﬁxed-dose combination treatment. Proportion of patients
(%) showing gradual changes
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flushing, congestive heart failure worsening/
decompensation, dyspnea, or arrhythmia.
There were only a few laboratory values
documented: fasting plasma glucose, HbA1C,
serum creatinine, aspartate aminotransferase,
and alanine aminotransferase. There were no
noticeable changes in these parameters during
the study.
DISCUSSION
Many patients with hypertension have other
concomitant conditions, including lipid
abnormalities, renal disease, diabetes,
cardiovascular events, obesity, and/or
smoking. The success of treating hypertension
has been limited, and despite well-established
approaches to diagnosis and treatment, fewer
than half of all hypertensive patients have
adequately controlled BP [21].
The most important goal of treatment is to
manage hypertension and to deal with the
other identified risk factors for cardiovascular
disease. For hypertension, the treatment goal
for systolic BP is usually \140 mmHg and for
diastolic BP \90 mmHg. Most patients will
require more than one drug to efficiently
control their BP. The choice of drugs will be
influenced by many different aspects and
conditions (e.g., diabetes and coronary
disease). Generally, there are many clinically
proven recommendations for drug selection
either for patients whose primary problem is
hypertension, or for patients who have a
major comorbidity associated with their
hypertension.
Table 4 Changes in systolic and diastolic BP after 6 months based on drug dose
Reduction of systolic BP mmHg Reduction of diastolic BP mmHg
Median 1–3 quartiles Median 1–3 quartiles
Bisoprolol 5 mg–amlodipine 5 mg 15 5–25 10 0–15
Bisoprolol 10 mg–amlodipine 5 mg 15 6–25 10 0–20
Bisoprolol 5 mg–amlodipine 10 mg 15 7–28 10 0–20
Bisoprolol 10 mg–amlodipine 10 mg 20 6–30 10 0–20
BP blood pressure
Fig. 2 Comparison of proportion of patients quartiles for systolic blood pressure values. FDC ﬁxed-dose combination
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As regards calcium channel blockers, most
experience with these agents has been gained
with the dihydropyridines, such as amlodipine
and nifedipine, which have shown beneficial
effects on cardiovascular and stroke outcomes
in hypertension trials [22]. Beta-blockers reduce
cardiac output and decrease the release of renin
from the kidney. They have strong clinical
outcome benefits in patients with histories of
myocardial infarction and heart failure and are
effective in the management of angina pectoris
[23, 24].
However, patients find having to take a large
number of tablets burdensome [24]. This
manifests itself in non-compliance with
treatment as directed, or discontinuation of
treatment [25]. Failure of hypertensive
treatment is demonstrably attributable mainly
to poor adherence to treatment on the part of
patients [26]. European guidelines for the
management of hypertension accordingly
recommend treatment with a combination
tablet [10] and the results of various studies
indicate the clinical relevance of this
recommendation [25, 27, 28].
The study results available to date
demonstrate the relationship between
successful BP management and patient
adherence, in particular since the results from
the first study period in more than 4000
patients corresponded fully to those generated
in the total population of more than 10,000
patients [20].
The cohort recruited in this study can be
considered as representative of real-life
hypertension treatment. The study covered a
wide range of ages: 23% of patients were aged
\50 years and 15% were aged[70 years, thus,
most patients were aged between 50 and
70 years. Good to excellent adherence was
Table 5 Correlation of BP after 6 months and adherence
Adherence Systolic BP
(mmHg)
Diastolic BP
(mmHg)
N5 8830 Mean (– SD) Mean (SD)
Median Median
Q1–Q3 Q1–Q3
Excellent
([90%)
N = 7562
130.5 (9) 79.1 (7)
130 80
125–136 75–83
Good (76–90%)
N = 1098
132.2 (11) 79.4 (8)
130 80
125–140 75–85
Moderate
(51–75%)
N = 145
137.1 (17) 76.7 (10)
140 80
120–150 70–85
Bad (\50%)
N = 25
144.1 (17) 79.8 (9)
140 80
127–160 70–88
BP blood pressure
Table 6 Dependence on systolic BP values and comorbidities prior to study entry
Comorbidity Disease present Disease absent
Systolic BP (mmHg) Systolic BP (mmHg)
Mean (–SD) Q1–median–Q3 Mean (–SD) Q1–median–Q3
Diabetes 150.7 (16) 140–150–160 146.4 (±15) 135–145–158
Cardiovascular diseases 149.5 (16) 140–150–160 145.9 (±15) 135–145–160
Renal diseases 149.1 (17) 140–150–160 147.2 (15) 139–147–160
BP blood pressure
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observed in more than 95% of patients, and
approximately 86% of prescribed tablets were
taken. It can be assumed that the investigators
helped to convince patients through intensive
discourse and that the consent of patients to
take part in this study likewise contributed to
this outcome. The consequence is a clinically
important decline in previously elevated
systolic BP in 82% of patients, and diastolic
BP in 73% of patients; BP declined overall by
11 percentage points. A therapeutic goal has
hence been met that is in line with
international guidelines. Regardless of the
doses prescribed in each case, similar
reductions in BP were achieved. Patients with
very high BP benefitted most from the use of
the FDC.
Comparison of results of the preceding study
with those of the overall group identified no
differences in the changes in BP, which is an
indication of rigorous and meticulous project
conduct. The results do not contradict those
obtained in investigational controlled trials [18,
19]. To that extent, the results of this
non-interventional study tend to contradict
the commonly postulated study design
hierarchy and confirm the insights of other
authors on this subject [29, 30].
Beyond that, this non-interventional study
provides insights into additional factors in the
lives of hypertension patients, in particular with
regard to their comorbidities and treatment
outcomes in these circumstances while
receiving routine medical care. The absence of
strict inclusion criteria, such as apply in RCTS,
enables data to be collected from patients with a
variety of comorbidities that may have a
meaningful impact on their condition and
may constitute additional risks.
The results of this study demonstrate that
systematic adherence with treatment
instructions contributes to a clinically relevant
improvement in BP control in these patients
too. The high acceptance of the FDC by the
patient was also shown by the fact that 97% of
patients preferred the FDC over the free
combination at study end.
Not only BP, but also the pulse pressure and
the heart rate as independent risk factors for
cardiovascular disease were improved in the
study. As far as the safety of treatment is
concerned, no AEs or reactions outside the
known profile for these active pharmaceutical
ingredients occurred during the 6-month
period.
The analysis of the study after 6 months was
based on the data of 8830 patients, which
represented a dropout rate of 17%. Experiences
in implementing observational studies show
that such a loss of data is quite common and
inevitable, and is unlikely to influence the
overall result of the study.
When evaluating the data from this study,
we paid more attention to clinically relevant
results than statistically calculated differences
or correlations, because the high number of
cases could lead to incorrect conclusions by
assessing statistical results only. To that extent,
the assessment of the results was more
orientated to differences in the confidence
intervals and the C values of the effect size
taken.
CONCLUSION
These study results suggest that high adherence
rates under a FDC of bisoprolol and amlodipine
may lead to better BP control and, thus, to risk
reduction for cardiovascular events. The
implementation of an observational study
with such a high number of patients provides
a wide range of information for daily practice
and enables us to draw conclusions about the
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relationships between the drug’s effect and
additional factors.
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